Search

BEIJING -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the [...]

- Four poster presentations, including two oral presentations, will highlight the clinical data for VTAMA cream for the treatment of atopic dermatitis in adults and children 2 years of age [...]

Phase 2 Initiation Supported by Positive Data from Phase 1 Studies in which ESK-001 was Generally Well-Tolerated and Demonstrated Full, Sustained TYK2 Inhibition SOUTH SAN FRANCISCO, Calif. -- Alumis Inc., [...]

Receives IND clearance for Phase 2b program in U.S. Topline data from ongoing Phase 2b clinical trial to be reported in Q4 2022 TEL AVIV, Israel & MELBOURNE, Australia -- [...]

DUBLIN -- The 'Acute Bacterial Skin and Skin Structure Infections - Pipeline Insight, 2022' clinical trials has been added to ResearchAndMarkets.com's offering. This 'Acute Bacterial Skin and Skin Structure Infections [...]

* Topical psoriasis treatments account for 42% of the $11.37 billion psoriasis drug market * Topline results from Phase III oral Piclidenoson study expected Q2 2022 * Piclidenoson has been [...]

Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets PETACH TIKVA, Israel -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a [...]

DUBLIN -- The 'Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023' report has been added to ResearchAndMarkets.com's offering. The global [...]

NEW DELHI -- Vyome Biosciences , a clinical-stage specialty biopharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today announced that it administered the first in-human [...]

SAINT PETERSBURG, Russia -- BCD-085 is an innovative drug containing a humanized monoclonal anti-interleukin-17 (anti-IL17) antibody as an active ingredient. The primary objective of the international multicenter double-blind placebo-controlled study [...]

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/fsdvq8/severe) has announced the addition of the 'Severe Psoriasis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016' report to their offering. Severe Psoriasis - [...]

DISCOVERY PARK, Sandwich, United Kingdom -- Ziarco Pharma Ltd., a biopharmaceutical company focusing on the development of novel drugs against inflammatory skin disorders, today announced that dosing has started in [...]

Company Positioned to Expand Clinical Dermatology Programs in 2015 DURHAM, N.C. -- Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced [...]

KNOXVILLE, Tenn. -- Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ('Provectus'), announced today that it has opened recruitment for its phase 2 mechanism of [...]

SEATTLE -- Kineta, Inc., a biotechnology company focused on the development of immune modulating drugs for critical diseases, announced today that the company has completed enrollment of its Phase 1B [...]

SEATTLE -- Kineta, Inc., a biotechnology company focused on the development of immune modulating drugs for critical diseases, announced today that the company has opened a Phase 1B proof-of-concept clinical [...]

-- Data Corroborates Potential Effectiveness in Mild to Moderate Plaque Psoriasis -- -- Milestone Has Increased Efforts to Seek Licensure of PH-10 for Treatment of Serious Dermatological Diseases - KNOXVILLE, [...]

The study will be conducted in 17 medical centers in the United States, Europe and Israel under an open IND PETAH-TIKVA, Israel -- Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company [...]

Multi-Center Randomized Trial Includes More Than 90 Subjects KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual in [...]

PALO ALTO, Calif. -- Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has completed enrollment in its Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of [...]

-Statistically significant improvement in primary endpoint of facial redness associated with rosacea- -Safety profile similar to placebo cream- MALVERN, Pa. -- Vicept Therapeutics, Inc. announced today positive study results from [...]

PETAH-TIKVA, Israel -- Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened Investigational New Drug application (IND) with the [...]

-Interim Data Indicates Effectiveness As a Potential Treatment --Seeking Licensure of PH-10 for Treatment of Serious Dermatological Diseases- KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology [...]

-- Third Phase 2 Completion of Patient Enrollment in Past Five Months -- KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development stage oncology and dermatology biopharmaceutical company, [...]

EMERYVILLE, Calif. & BRISBANE, Australia -- Peplin, Inc. (ASX:PLI) today announced the initiation of two Phase 3 clinical trials to confirm the efficacy and safety of PEP005 (ingenol mebutate) Gel [...]

Company Seeking Approval for the Treatment of Complicated Skin and Soft Tissue Infections in Europe CAMBRIDGE, Mass. -- Targanta Therapeutics Corporation (Nasdaq: TARG) today announced that the European Medicines Agency [...]

Study Builds on Phase 1 Safety and Preliminary Efficacy Results for PH-10 KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) has obtained approval to begin Phase 2 clinical testing of [...]

The Market for Psoriasis Therapies is Estimated at About USD 3 Billion The Company Has Also Completed the Clinical Portion of a Phase IIb Clinical Trial for the Treatment of [...]

STOCKHOLM, Sweden -- The biopharma company Biovitrum (STO:BVT), listed on the Stockholm Stock Exchange since September 15, 2006, entered an agreement with the Uppsala-based biotech company Synphora in the autumn [...]

STOCKHOLM, Sweden -- The biopharma company Biovitrum (STO:BVT), listed on the Stockholm Stock Exchange since September 15, 2006, has entered an agreement with the Uppsala-based biotech company Synphora regarding a [...]

PETACH TIKVA, Israel -- Psoriasis is a Skin Condition That Affects 2% to 3% of the General Population; the Market Share for Psoriasis Drugs is Estimated at US$ 3 Billion [...]

MISSISSAUGA, Ontario--(Health Wire)--April 19, 1995--DUSA Pharmaceuticals Inc. (NASDAQ NMS:DUSA; TSE:DSP) reported today the initiation of a pilot human clinical study using the Company's ALA photodynamic therapy (PDT) in the treatment [...]